HOW DO THE JUDGES SELECT THE SCRIP AWARDS WINNERS?
The Scrip Awards prides itself on its independent Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility. The judges each separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience, ensuring a considered response to each individual submission. Each category is reviewed by at least three judges.
Winter is master of Trinity College, Cambridge and a fellow of the Royal Society. He is a scientist, inventor and entrepreneur and best known for his research and inventions relating to therapeutic antibodies made at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.
He has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009.
Winter is master of Trinity College Cambridge and until recently a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge.
Hargreaves is an independent adviser for private equity. His career in healthcare spans academia, pharma, venture capital and private equity.
Following his early career as a lecturer in pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle which included the commercialisation of the blockbuster Nexium. In 1997, he moved to 3i plc in the innovative growth period of biotech venture capital. More lately he originated several significant growth capital deals and buyouts.
He currently advises selected private equity firms and spends a proportion of his time in the charity sector.
Halloran is the president of Halloran Consulting Group (HCG), founded in 1998. With over 30 years in life science management, she has become recognised as an industry expert through her group’s work in conceiving, nurturing, transforming and repairing life science companies.
In 2015, Halloran was honored by the Boston Business Journal as a Woman of Influence, and the company has received a ranking in the INC 500 fastest growing companies for the past 2 years. In 2010, Halloran was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice and in 2009, she was awarded clinical researcher of the year by ACRP.
Winquist is the current president of Pharma Research and Discovery Consulting, advising companies and firms on best practice for developing novel therapeutics.
He is the previous co-site head of research; vice president of integrated biology at Vertex Pharmaceuticals and vice president of pharmacology at Scion Pharmaceuticals.
Has gained an NIH postdoctoral fellowship in Physiology, a PhD. in Pharmacology, a masters in scientific instrumentation, physics department, and a bachelor of arts in biological sciences.
Brown is an independent pharmaceutical project management, QA and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 20 years of experience of managing clinical development projects, and training in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and LB Training and Development. She is also co-author of several books including ‘Project Management for the Pharmaceutical Industry’.
Gillings is recognised as a visionary pioneer in the contract research organisation industry. He is co-founder and former executive chairman of Quintiles Transnational, the world’s largest biopharmaceutical services company. Gillings retired as executive chairman in 2015, although he remains on the board of the Fortune 500 company.
In 2014, Gillings was appointed World Dementia envoy by former UK Prime Minister David Cameron. In this capacity he chaired the World Dementia Council, an organization that seeks to stimulate innovation to treat cognitive decline.
As envoy, he worked with governments to provide a global leadership role in addressing the economic, regulatory and social barriers to innovation in dementia prevention, treatment, and care. Gillings has seen firsthand the devastating effects of dementia and lack of effective treatment, as his mother lived with the condition for 18 years until her death in 2013.
Prior to founding Quintiles, Gillings was a professor of biostatistics at the University of North Carolina at Chapel Hill for more than 15 years. Among the many honours he has received, Gillings was awarded a CBE in 2004 for services to the pharmaceutical industry. In 2012, he received the SCRIP Lifetime Achievement Award in recognition of contributions to pharmaceuticals.
Jones is chairman of Simbec-Orion Group. He was formerly R&D director of The Wellcome Foundation (UK), a director of Allergan Inc. (USA) and director general of the association of the British Pharmaceutical Industry (ABPI). He is a visiting professor at King’s College, London.
Mehta founded and is managing member of Mehta Partners. His wide-ranging perspective and analytical insights on global health care have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior biopharma leaders and investment managers, as well as private and public health care policy makers and providers, for about 30 years.
Mehta began his career with Merck & Co in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company to invite him to establish a pharmaceutical research function in New York. This effort was expanded at SG Warburg & Company, and led to the formation of the biopharma investment advisory group Mehta and Isaly, now known as Mehta Partners.
Since 2012, Messom has been chairman of the Institute of Clinical Research; the oldest independent membership lead professional body for global clinical researcher. With a background in molecular genetics, Messom has almost 20 years industry experience working both within pharmaceutical companies and clinical research organisations. Messom has detailed experience of directing global clinical trials and has worked in a wide variety of leadership roles, within pharma companies and CROs for not only project and monitoring teams, but also data management, outsourcing, informatics and translational medicine departments. Most recently she has provided consultancy support to an academic group working on a translational medicine project and operational consultancy to a mid-sized pharma company working in phase III & IV.
Phacharintanakul is chairman of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chairman of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.
Pitts is president of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service (SES), Pitts was FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the Commissioner. He supervised FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee (SGE) consultant to the FDA’s Risk Communications Advisory Committee.
Specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, DTC/ItP, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling.
Tempest has worked in the pharmaceutical industry for the last 44 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 he held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Previously, Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net-worth individuals on their strategy in Asia. Tempest is a non-executive director of SRL Diagnostics, Fortis Healthcare, and Glenmark Pharmaceuticals. Currently he is editor of the Journal of Generic Medicines.
Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies, and serves as an advisor to Warburg Pincus. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. Spiegel is a fellow of the American College of Physicians and has received numerous awards and fellowships. He serves on the boards of many biotechnology companies and non-profit organizations, and is an assistant professor Weill Cornell Medical School and associate fellow in the University of Pennsylvania Center for Bioethics.
Thong consults on business strategy and collaborations in the bioscience sector. He also writes a regular blog on these topics. Thong’s full-length book, ‘Biopharma R&D Partnerships: From David & Goliath to Networked R&D’, was published in January 2016, derived from the practical experiences of over forty different organisations. He has previously been co-head of the Cap Gemini Life Sciences Group, managing director of Datamonitor’s healthcare division, a non-executive board member of the listed US mid-sized pharmaceutical company Alpharma, and a co-founder of two specialist consultancies focusing respectively on mid-sized biopharma companies and change management for scientific organisations.
Smith commenced his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and with Glaxo, after completing an MBA Smith switched to a commercial role at SB Pharmaceuticals and was appointed as global brand manager for Bactroban and new products in the Anti-Infectives Global Marketing Group.
In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for three life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.
After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years.
Smith returned to specialist fund management in 2012 and is the fund manager of the Magna Biopharma Income Fund.
Scrip Awards is part of the Business Intelligence Division of Informa PLC